277 related articles for article (PubMed ID: 31317680)
1. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
[TBL] [Abstract][Full Text] [Related]
2. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
3. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
[TBL] [Abstract][Full Text] [Related]
6. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Borghi C; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
Yan CQ; Liang C; Lan ZR; Su C; Xiong SY; Yang YX; Chen JM; Tang SL; Huang JS; Zhang ZH; Luo MJ; Xiao ZH
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11988-12003. PubMed ID: 38164861
[TBL] [Abstract][Full Text] [Related]
8. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Kim JW; Kwak SG; Park SH
Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
[No Abstract] [Full Text] [Related]
9. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
10. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F; Chen L; Du Y
Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
[TBL] [Abstract][Full Text] [Related]
12. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Ellmann H; Bayat S; Araujo E; Manger B; Kleyer A; Cavallaro A; Lell M; Schenker H; Simon D; Tascilar K; Baraf HSB; Schett G; Rech J
Arthritis Rheumatol; 2020 Jan; 72(1):150-156. PubMed ID: 31353871
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
15. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
16. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
18. Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.
Kim HA; Seo YI; Song YW
J Korean Med Sci; 2014 Aug; 29(8):1077-81. PubMed ID: 25120316
[TBL] [Abstract][Full Text] [Related]
19. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
20. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
